The present information document supplements the WHO audited financial statements for 2018. It contains information on WHO's voluntary contributions by fund and by contributor in the year 2018.
A year ago, the second Special Session of the World Health Assembly (WHASS) unanimously agreed to start a diplomatic process for a new binding instrument aimed at ensuring the international community is better prepared for the next health emergencies. The establishment of an Intergovernmental Negoti...ating Body (INB) at the WHO paved the terrain for a proper negotiation, which has started to unfold. The INB will be releasing the “conceptual zero draft” of the treaty text in early December 2022.
more
It is estimated that more than 311 000 women die of cervical
cancer each year. Of these deaths, 91% occur in low- and
middle-income countries. Demographic changes and a lack of
action mean that the number of deaths per year is projected
to reach 460 000 by 2040.
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig...h disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
The path to elimination provides a framework with 3 levels of achievements for which WHO certification is available. Each stepwise progression from bronze to silver to gold tiers will promote an iterative expansion of prevention, diagnosis and treatment services for viral hepatitis services and strengthen measurement systems to support attainment of the 2030 elimination goals.
This updated version also includes changes, clarifications and new guidance on alternative measurement approaches for country validation of elimination. Through the validation process, WHO and partners continue to provide country support for strengthening health system capacity and patient-centred services that respect and protect the human rights of people living with viral hepatitis and ensures meaningful engagement of communities in the national, regional and global viral hepatitis response.
more
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr...ess the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more
Dieser Bericht enthält eine neue Strategie für Investitionen in die Gesundheit als Beitrag zur Wirtschaftsentwicklung, vor allem in den ärmsten Ländern der Welt, auf der Grundlage einer neuen globalen Partnerschaft zwischen sich entwickelnden und entwickelten Ländern. Zügiges und mutiges Hande...ln könnte zum Ende dieser Dekade mindestens 8 Millionen
Menschenleben pro Jahr retten, die Lebensdauer und die Leistungsfähigkeit der Armen erhöhen und ihre wirtschaftliche Lage verbessern Hierfür wären zwei wichtige Initiativen zu ergreifen: eine deutliche Erhöhung der Mittel, die für Gesundheit ausgegeben werden,sowohl durch die armen Länder als auch durch die Geber und eine Beseitigung der nichtfinanziellen Hindernisse, die arme Länder in ihrer Fähigkeit zur Bereitstellung von Gesundheitsdiensten einschränken
more
The world has been turned on its head by the coronavirus disease 2019 (COVID-19) pandemic. This has provided a stark wakeup call on the severe under-financing of health systems around the world. It has laid bare the inequalities and limitations in the capacities of countries at all levels of develop...ment to prevent major health crises or respond to them. But it doesn’t have to be this way.
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
The KMC implementation strategy targets a broad audience. These include policy-makers and programme managers at national, regional and local levels, government and nongovernmental organizations working in the area of maternal and newborn care, global and national professional associations, public an...d private hospital management at all levels of care, and facility- and community-based maternal and infant care providers.
more
Objetivos:
- Reforzar la importancia del informe anatomopatológico en el manejo del cáncer
de mama, como elemento fundamental para la toma de decisiones.
- Estandarizar los procedimientos de las técnicas anatomopatológicas a nivel
nacional.
- Establecer los factores pronósticos morfoló...gicos, inmunohistoquímicos y
moleculares validados actualmente.
- Establecer un protocolo de informe anatomopatológico completo, reproducible y
estandarizado, orientado a contribuir en el manejo clínico y en la elaboración de
bases de datos.
more
Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th...at would guide national programme managers in collaboration with their respective oversight committees on when to stop mass drug administration (MDA) and conduct post-treatment surveillance (PTS) activities for a minimum period of 3 to 5 year before confirming the interruption of transmission of Onchocerca volvulus parasite and hence its elimination. They also include steps to undertake for verification of elimination of transmission of the parasite in the whole endemic country by the International Verification Team (IVT) prior to the official acknowledgement by WHO Director General.
more
В дорожной карте по борьбе с забытыми тропическими болезнями на 2021–2030 гг. («дорожная карта») определены глобальные цели и основные этапы в отношении борьбы с 20 бол...знями и группами болезней, их элиминации или полной ликвидации. В ней также определены сквозные целевые показатели, согласованные с Тринадцатой общей программой работы ВОЗ и Целями в области устойчивого развития, а также стратегии по достижению этих целевых
показателей в течение ближайших десяти лет.
more
Este informe es el primero de la serie «Intención de pasar a la acción» de la OMS, cuyo objetivo es mejorar la limitada base de evidencia sobre la repercusión de la participación constructiva y abordar la falta de enfoques normalizados sobre cómo hacer operativa dicha participación. La serie... «Intención de pasar a la acción» pretende conseguirlo proporcionando una plataforma desde la que personas con experiencias vividas, y defensores de organizaciones e instituciones, puedan compartir soluciones, dificultades y prácticas prometedoras relacionadas con esta agenda transversal. Esta serie también tiene como objetivo proporcionar poderosas historias, inspiración y evidencia de cara a la Cuarta Reunión de Alto Nivel de las Naciones Unidas sobre las ENT que se celebrará en 2025, así como lograr los Objetivos de Desarrollo Sostenible (ODS) de las Naciones Unidas para 2030.
Para ello, este informe incluye seis estudios de casos procedentes de 12 personas con experiencias vividas de diversas dolencias. Se analizan temas como la dinámica del poder y la reorientación del poder hacia las personas con experiencias vividas; la toma de decisiones informada y la alfabetización sanitaria; la implicación de la comunidad en redes sanitarias y sistemas de salud más amplios; la experiencia vivida como evidencia y conocimientos; la exclusión y la importancia de implicar a los grupos que están marginados; y la promoción y los derechos humanos
more
This report includes six case studies from 12 individuals with lived experience of diverse health conditions. These case studies explore the topics of power dynamics and power reorientation towards individuals with lived experience; informed decision-making and health literacy; community engagement ...across broader health networks and health systems; lived experience as evidence and expertise; exclusion and the importance of involving groups that are marginalized; and advocacy and human rights.
It is the first publication in the WHO Intention to action series, which aims to enhance the limited evidence base on the impact of meaningful engagement and address the lack of standardized approaches on how to operationalise meaningful engagement. The Intention to action series aims to do this by providing a platform from which individuals with lived experience, and organizational and institutional champions, can share solutions, challenges and promising practices related to this cross-cutting agenda. The Intention to action series also aims to provide powerful narratives,inspiration and evidence towards the Fourth United Nations High Level Meeting on NCDs in 2025 and achieving the 2030 United Nations Sustainable Development Goals (SDGs).
more
The road map sets global targets and milestones to prevent, control, eliminate or eradicate 20 diseases and disease groups as well as cross-cutting targets aligned with the Sustainable Development Goals. Three foundational pillars will support global efforts to achieve the targets: accelerate progra...mmatic action (pillar 1), intensify cross-cutting approaches (pillar 2) and change operating models and culture to facilitate country ownership (pillar 3).
more
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more
This Quick Reference Handbook of Selected Congenital Anomalies and Infections is a companion tool to Birth defects surveillance: a manual for programme managers, and is intended for use by front-line health care professionals who are diagnosing and collecting data on congenital defects and infection...s. When used in conjunction with the manual, the tools in this handbook will help the reader to: identify an initial list of congenital anomalies to consider for monitoring;describe the tools needed to define and code identified cases; define specific congenital anomalies under surveillance.
more
Un comité OMS d’experts sur la trypanosomiase humaine africaine (THA) : lutte et surveillance, s’est réuni à Genève (Suisse), du 22 au 26 avril 2013. Le Dr H. Nakatani, sous-directeur général pour le VIH/SIDA, la tuberculose, le paludisme et les maladies tropicales négligées, a ouvert la... réunion au nom du Dr M. Chan, directeur-général de l’OMS.
La THA est une maladie qui afflige les populations rurales de l’Afrique, là où prolifère la mouche tsé-tsé (ou glossine), vecteur des trypanosomes qui en sont la cause. On distingue deux formes de THA : la forme à T. b. gambiense ou forme gambienne, endémique en Afrique de l’Ouest et en Afrique centrale et qui
représente actuellement 95 % des cas, et la forme à T. b. rhodesiense ou forme rhodésienne, endémique en Afrique de l’Est et en Afrique australe, à laquelle sont dus les 5 % restants.
more
Background: One of the objectives of the Global Action Plan by the World Health Organization (WHO) to contain antimicrobial resistance (AMR), is to improve global awareness through effective communication and education. Comprehensive information on the level of awareness of AMR among Nigerian public... is deficient. This study was therefore designed to assess the current level of awareness and knowledge of the Nigerian public of AMR.
more
Les présentes lignes directrices ont pour objet de préparer les pays d’endémie à arrêter l’AMM à l’issue du traitement, à passer à la surveillance post-thérapeutique ainsi qu’à confirmer l’interruption de la transmission à l’issue de la phase 2 et à débuter la surveillance p...ost-élimination.
Le but est de fournir un outil actualisé pour atteindre et vérifier l’élimination de la
transmission d’Ovolvulus à l’issue des programmes d’élimination de l’onchocercose qui utilisent principalement l’AMM.
Les objectifs sont de :
• formuler des recommandations basées sur des preuves à l’intention des prestataires de soins et des décideurs en matière de politique pour démontrer et confirmer l’interruption de la transmission d’O. volvulus avant, pendant et après la surveillance post-thérapeutique ;
• informer les utilisateurs finaux des procédures nécessaires pour vérifier l’élimination de l’onchocercose humaine.
more